Calithera to Present at Needham & Company 17th Annual Healthcare Conference
March 23 2018 - 8:00AM
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage
biotechnology company focused on the development of novel cancer
therapeutics, today announced that Keith Orford, M.D., Ph.D, the
company’s Senior Vice President of Clinical Development, will
present at the Needham & Company 17th Annual Healthcare
Conference at 2:00 p.m. ET on Wednesday, March 28, 2018 in New York
City. The presentation will be webcast live and available for
replay for up to 30 days at www.calithera.com in the Investor
Relations section.
About Calithera
Calithera is a clinical-stage biopharmaceutical company focused
on fighting cancer by discovering, developing, and commercializing
novel small molecule drugs that target tumor and immune cell
metabolism. Calithera is headquartered in South San Francisco,
California. For more information about Calithera, please
visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Words such as "may," "will," "expect," "anticipate,"
"estimate," "intend," "poised" and similar expressions (as well as
other words or expressions referencing future events, conditions,
or circumstances) are intended to identify forward-looking
statements. These statements include those related to the
safety, tolerability and efficacy of CB-839, the overall
advancement of CB-839 in clinical trials, the unmet need in the
treatment of patients with advanced disease, and Calithera’s plans
to continue development of CB-839 in combination with everolimus
for the treatment of clear cell renal cell carcinoma. Because
such statements are subject to risks and uncertainties, actual
results may differ materially from those expressed or implied by
such forward-looking statements. The product candidates that
Calithera develops may not progress through clinical development or
receive required regulatory approvals within expected timelines or
at all. In addition, clinical trials may not confirm any safety,
potency or other product characteristics described or assumed in
this press release. Such product candidates may not be
beneficial to patients or successfully commercialized. The
failure to meet expectations with respect to any of the foregoing
matters may have a negative effect on Calithera's stock
price. Additional information concerning these and other risk
factors affecting Calithera's business can be found in Calithera's
most recent Annual Report on Form 10-K filed with the Securities
and Exchange Commission, and other periodic filings with the
Securities and Exchange Commission at www.sec.gov. These
forward-looking statements are not guarantees of future performance
and speak only as of the date hereof, and, except as required by
law, Calithera disclaims any obligation to update these
forward-looking statements to reflect future events or
circumstances.
SOURCE: Calithera Biosciences,
Incorporated
CONTACT:
Jennifer McNealeyir@Calithera.com650-870-1071
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Apr 2023 to Apr 2024